What are Monoclonal Antibodies?
Monoclonal antibodies (mAbs) are immunoglobulins that exhibit a high level of specificity toward a single antigen or epitope. These antibodies are produced from a single B-cell clone, resulting in identical immunoglobulins with precise binding capabilities.
Key Takeaways
- Monoclonal antibodies (mAbs) are derived from a single B-cell clone or defined recombinant sequence and recognize a single epitope. In contrast, polyclonal antibodies are produced by multiple B-cell clones and recognize multiple lineages and bind several epitopes on the same antigen.
- Six development methods are used to generate mAbs, which can be generated through platforms such as hybridoma, phage display, single-B-cell isolation and recombinant expression. Chimerization, chimeric and humanized are antibody-engineering strategies used to modify selected antibodies, rather than as separate production methods or animal use.
- Unconjugated Naked, conjugated and bispecific mAbs represent three structurally distinct classes. Among the three common therapeutic formats, unconjugated antibodies act without an attached payload; conjugated antibodies deliver a linked drug or radionuclide; and bispecific antibodies recognize two distinct epitopes or antigens, as exemplified by dual-target bispecifics like blinatumomab.
- mAbs are used across research applications such as (immunoassays and affinity, protein purification; in diagnostic assays, including some), diagnostics (pregnancy tests and testing, cancer biomarker tests; screening) and as therapeutics for conditions including (cancer, autoimmune and inflammatory diseases and certain diseases, infectious diseases).
- After production, mAbs still require purification and additional processing appropriate to their intended use. Protein A or G (commonly used for many IgG antibodies, often followed by polishing steps such as ion-exchange chromatography) is required before they are suitable for research or clinical use; they also require viral clearance, formulation and stringent quality-control steps, which this page does not currently cover.
Monoclonal Antibody Mechanisms of Action
Monoclonal antibodies act by specifically binding to target antigens or epitopes on cells or molecules. This targeted binding can block signaling pathways, interfere with protein-protein interactions or prevent receptor-ligand interactions, thereby modulating cellular function and immune response. mAbs structures can also be engineered to serve as carriers for delivering therapeutic agents (antibody-drug conjugates; ADCs) directly to target cells, enabling selective and precise treatment delivery. Furthermore, specific mAbs can trigger immune-mediated cytotoxicity or disrupt tumor blood vessel formation, thereby inhibiting tumor growth.
Types of Monoclonal Antibodies
Naked Monoclonal Antibodies
- Naked mAbs function independently without any attached drugs or radioactive materials, operating solely based on their inherent properties
Conjugated Monoclonal Antibodies
- Conjugated mAbs have been linked or combined with a chemotherapy drug or a radioactive particle
Bispecific Monoclonal Antibodies
- Bispecific mAbs are specialized antibody molecules designed to bind to two different target proteins simultaneously. For instance, blinatumomab binds to the CD19 protein (found on certain leukemia and lymphoma cells) and the CD3 protein on T cells. This dual binding mechanism brings cancer and immune cells together, potentially leading to immune system-mediated attacks on cancer cells.
Types of Monoclonal Antibody Development Methods
Hybridoma
Hybridoma technology is a widely used approach for producing mAbs. This mAb development process typically includes immunizing animals with the target antigen, isolating antibody-producing B cells, fusing B cells with myeloma cells to form hybridoma cells, screening and selecting desired antibody-producing hybridomas and subsequently culturing and harvesting mAbs from the selected hybridoma clones. During the development process, antibody characterization is crucial to assess the antibodies’ quality, potency and specificity.
Phage Display
Phage display is a technique that involves expressing antibody fragments on the surface of bacteriophages to display human antibody fragments. These phages can then be screened for their binding affinity to a specific target antigen, thereby identifying high-affinity antibodies.
Single B Cell
Single B cell technology enables the production of mAbs with native heavy- and light-chain pairings by directly amplifying Ig genes from individual human B cells. These genes are expressed in cell culture, preserving the natural antibody diversity. This method increases the likelihood of generating mAbs that recognize complex, conformational epitopes that are difficult to mimic in vivo.
Recombinant Antibodies
Recombinant technology uses genetic engineering to encode specific antibodies. These genes are introduced into expression systems, such as bacteria, yeast or mammalian cells. Recombinant mAb creates custom antibodies by allowing the generation of hybrid antibody structures with unique characteristics.
Chimeric Antibodies
Chimeric mAbs are molecules composed of segments fused from different species. For example, the Fc (constant) domains (scaffolding) could be human-derived and the binding (variable) region could be derived from a mouse.
Humanized Antibodies
Humanized antibody production utilizes immunized in vivo models, such as mice, with target antigens. These antibodies are then mostly human in sequence, with only the antigen-binding sites (complementarity-determining regions) from the mouse. This generates human mAbs with greater diversity and affinity.
Ensuring Product Quality Attributes
Despite the method of development, mAbs can exhibit heterogeneity due to enzymatic and nonenzymatic modifications, such as incomplete disulfide bond formation, glycosylation, N-terminal cyclization, C-terminal lysine processing, deamidation, isomerization, oxidation and other post-translational modifications. When developing mAbs for therapeutic use, it is important to consider and test binding affinity, stability, purity and potency throughout the production process.
Purification of Monoclonal Antibodies
Once produced, monoclonal antibodies must be separated from cells, media components and other impurities. Protein A or Protein G affinity chromatography is commonly used to capture many IgG antibodies, followed by polishing methods such as ion-exchange chromatography to improve purity further. The optimal workflow depends on factors including antibody isotype and format, expression system, scale and intended use. Effective purification helps support antibody purity, stability and performance in downstream assays or formulations.
Danaher's chromatography columns and HPLC systems support these purification and characterization steps see Chromatography Columns and High Performance Liquid Chromatography (HPLC) Systems.
Applications of Monoclonal Antibodies
- mAbs serve as indispensable tools in laboratory research. They are used in analytics and chemical research, including immunoassays, research tools, protein purification and drug development processes that play a critical role in tissue and blood typing.
- mAbs are regularly used in diagnostics such as pregnancy testing, screening and monitoring of cancers and analysis of hormonal disorders.
- mAbs therapeutics can potentially minimize side effects and improve patient outcomes. mAb Treatments include complications of viral infections, cancer, radioimmunotherapy, treatment of asthma, AIDS and COVID-19.
- Examples of mAbs in treatment include Rituximab, Trastuzumab, Pembrolizumab, Adalimumab, Bevacizumab and Eculizumab, which are used for the treatment of various conditions such as cancer, autoimmune diseases, inflammatory disorders and rare blood disorders.
Advancements in Monoclonal Antibodies
Cell Line Development
Cell line development plays a crucial role in the future of antibody engineering. It enables the generation of stable cell lines to produce engineered recombinant antibodies with improved properties, such as enhanced affinity, specificity and stability. However, this process is cumbersome and ripe for automation and innovation to speed up development and manufacturing while ensuring critical quality attributes are not adversely affected.
Combination Therapies
Combination therapies are emerging as a promising approach, in which mAbs are used alongside other therapies such as chemotherapy, immune checkpoint inhibitors or targeted small molecules.
Personalized Medicine and Biomarkers
The future of mAbs also involves personalized medicine and biomarkers, in which specific patient characteristics and biomolecular signatures are used to tailor antibody treatments. This approach allows for individualized dosing, treatment selection and improved patient outcomes.
Novel Applications in Imaging
Furthermore, there is growing interest in using mAbs for novel applications, such as imaging. Antibodies can be engineered or conjugated with imaging agents to enable precise disease detection, imaging of specific targets and monitoring of treatment response, opening new avenues for early diagnosis and therapeutic monitoring.
See how Danaher Life Sciences can help
Featured Product
Monoclonal Antibodies (mAbs)
ClonePix 2 Mammalian Colony Picker
Automated colony picking for antibody discovery and cell line development. Screens and selects high-value clones from semi-solid media, so promising hybridoma and mammalian clones are identified and expanded without manual picking.
DispenCell Single-Cell Dispenser
Compact single-cell dispenser for gentle, label-free isolation. Seeds one cell per well and records imaged evidence of the dispense, supporting single B cell workflows and clonality documentation.
See how Danaher Life Sciences can help
FAQs
What is the difference between monoclonal and polyclonal antibodies?
Monoclonal antibodies are produced from a single B-cell clone, resulting in identical immunoglobulins that bind to a single epitope of an antigen. Polyclonal antibodies are produced by multiple B cells. They bind to different epitope regions of the same antigen.
How are monoclonal antibodies produced?
There are several methods for producing AMBs. These methods include but are not limited to hybridoma, phage display, single B-cell, recombinant, chimeric and humanized.
How do monoclonal antibodies work?
Monoclonal antibodies function by specifically binding to target epitopes on antigens found on cells or molecules. This targeted binding can disrupt signaling pathways, block protein-protein interactions or inhibit receptor-ligand interactions, thereby modulating cellular function and immune response.
What is the structure of a monoclonal antibody?
A monoclonal antibody is composed of two heavy chains and two light chains, connected in a Y-shaped configuration. The variable regions at the tips of the arms form the antigen-binding site. In contrast, the constant regions, including the Fc region on the heavy chains, determine the antibody's effector function.
How are monoclonal antibodies purified?
Purification typically uses affinity chromatography with protein A or protein G ligands, ion-exchange chromatography or precipitation-based methods, with the choice guided by the antibody's isotype and intended use.
What are examples of monoclonal antibody drugs?
Examples include rituximab, trastuzumab, pembrolizumab, adalimumab, bevacizumab and eculizumab, used respectively in conditions such as lymphoma, HER2-positive breast cancer, immune checkpoint inhibition in cancer, autoimmune and inflammatory disease, anti-angiogenic cancer therapy and rare blood disorders.